GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh Tracks Therapeutics Inc (STU:VCC) » Definitions » Cyclically Adjusted Revenue per Share

Fresh Tracks Therapeutics (STU:VCC) Cyclically Adjusted Revenue per Share : €0.00 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Fresh Tracks Therapeutics Cyclically Adjusted Revenue per Share?

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Fresh Tracks Therapeutics's adjusted revenue per share for the three months ended in Dec. 2023 was €0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.00 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Fresh Tracks Therapeutics's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Fresh Tracks Therapeutics was 4.20% per year. The lowest was -17.00% per year. And the median was -6.60% per year.

As of today (2024-05-16), Fresh Tracks Therapeutics's current stock price is €0.687. Fresh Tracks Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was €0.00. Fresh Tracks Therapeutics's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Fresh Tracks Therapeutics was 10.53. The lowest was 0.01. And the median was 0.79.


Fresh Tracks Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Fresh Tracks Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresh Tracks Therapeutics Cyclically Adjusted Revenue per Share Chart

Fresh Tracks Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 502.12 410.75 333.89 283.21 -

Fresh Tracks Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 283.21 286.31 274.42 283.42 -

Competitive Comparison of Fresh Tracks Therapeutics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Fresh Tracks Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fresh Tracks Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fresh Tracks Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Fresh Tracks Therapeutics's Cyclically Adjusted PS Ratio falls into.



Fresh Tracks Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Fresh Tracks Therapeutics's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/129.4194*129.4194
=0.000

Current CPI (Dec. 2023) = 129.4194.

Fresh Tracks Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 63.179 99.695 82.016
201406 118.429 100.560 152.417
201409 92.103 100.428 118.691
201412 134.862 99.070 176.177
201503 157.517 99.621 204.633
201506 128.310 100.684 164.930
201509 154.138 100.392 198.707
201512 215.655 99.792 279.680
201603 142.552 100.470 183.626
201606 126.517 101.688 161.019
201609 71.333 101.861 90.632
201612 85.686 101.863 108.866
201703 85.629 102.862 107.737
201706 87.000 103.349 108.946
201709 75.500 104.136 93.831
201712 58.596 104.011 72.910
201803 8.420 105.290 10.350
201806 9.116 106.317 11.097
201809 0.580 106.507 0.705
201812 1.580 105.998 1.929
201903 75.366 107.251 90.944
201906 0.000 108.070 0.000
201909 16.523 108.329 19.740
201912 3.202 108.420 3.822
202003 4.688 108.902 5.571
202006 2.049 108.767 2.438
202009 0.194 109.815 0.229
202012 0.018 109.897 0.021
202103 0.010 111.754 0.012
202106 0.082 114.631 0.093
202109 0.060 115.734 0.067
202112 0.038 117.630 0.042
202203 0.032 121.301 0.034
202206 1.537 125.017 1.591
202209 0.169 125.227 0.175
202212 0.642 125.222 0.664
202303 0.002 127.348 0.002
202306 0.008 128.729 0.008
202309 1.259 129.860 1.255
202312 0.000 129.419 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Fresh Tracks Therapeutics  (STU:VCC) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Fresh Tracks Therapeutics was 10.53. The lowest was 0.01. And the median was 0.79.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Fresh Tracks Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Fresh Tracks Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Fresh Tracks Therapeutics (STU:VCC) Business Description

Industry
Traded in Other Exchanges
Address
5777 Central Avenue, Suite 102, Boulder, CO, USA, 80301
Fresh Tracks Therapeutics Inc is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics.

Fresh Tracks Therapeutics (STU:VCC) Headlines

No Headlines